LiverLearning®: 2019 Webinar: The 2018 Primary Biliary Cholangitis Practice Guidance: Highlights

In this webinar, Drs. Marlyn Mayo and Cynthia Levy will discuss the most important recommendations included in the 2018 PBC Practice Guidance document. We will utilize a prerecorded webinar format for on-demand viewing on Liver Learning ® .Cynthia Levy Cynthia Levy, MD, FAASLD is a Professor of Medicine in the Division of Digestive Health and Liver Diseases and is the Associate Director of the Schiff Center for Liver Diseases at the University of Miami. She was awarded the Arthur Hertz Endowed Chair in Liver Diseases. Dr. Levy received her M.D.

Liver Imaging Reporting and Data System Version 2018: Impact on Categorization and Hepatocellular Carcinoma Staging

Victoria Chernyak, Milana Flusberg, Jesse Berman, Kate C. Fruitman, Mariya Kobi, Kathryn J. Fowler, Claude B. Sirlin – 25 July 2019 – The purpose of this study was to assess the concordance in categorization and radiologic T staging using Liver Imaging Reporting and Data System (LI‐RADS, LR) version 2017 (v2017), version 2018 (v2018), and the Organ Procurement and Transplantation Network (OPTN) criteria. All magnetic resonance imaging and computed tomography reports using a standardized LI‐RADS macro between April 2015 and March 2018 were identified retrospectively.

Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidase‐A/5‐Hydroxytryptamine/5‐Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis

Konstantina Kyritsi, Lixian Chen, April O’Brien, Heather Francis, Travis W. Hein, Julie Venter, Nan Wu, Ludovica Ceci, Tianhao Zhou, David Zawieja, Anatoliy A. Gashev, Fanyin Meng, Pietro Invernizzi, Luca Fabris, Chaodong Wu, Nicholas J. Skill, Romil Saxena, Suthat Liangpunsakul, Gianfranco Alpini, Shannon S. Glaser – 25 July 2019

Redefining Cirrhotic Cardiomyopathy for the Modern Era

Manhal Izzy, Lisa B. VanWagner, Grace Lin, Mario Altieri, James Y. Findlay, Jae K. Oh, Kymberly D. Watt, Samuel S. Lee, on behalf of The Cirrhotic Cardiomyopathy Consortium – 25 July 2019 – Cirrhotic cardiomyopathy (CCM) is cardiac dysfunction in patients with end‐stage liver disease in the absence of prior heart disease. First defined in 2005 during the World Congress of Gastroenterology, CCM criteria consisted of echocardiographic parameters to identify subclinical cardiac dysfunction in the absence of overt structural abnormalities.

Subscribe to